Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Completed
- Conditions
- Ocular Surface DiseasePrimary Open Angle Glaucoma
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 50
- Registration Number
- NCT04828057
- Locations
- 🇨🇳
Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital, Taoyuan city, Taiwan
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Not Applicable
Completed
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 1
- Registration Number
- NCT04737928
- Locations
- 🇨🇳
Chi Mei Hospital Liouying Branch, Tainan, Taiwan
© Copyright 2025. All Rights Reserved by MedPath